Xeltis CTO on the future of heart valve therapy at PCR London Valves
22 . 09 . 2017

Xeltis CTO on the future of heart valve therapy at PCR London Valves

Martijn Cox, Xeltis’ CTO, will share his vision on the future of cardiovascular treatment during the “Where will we be in 2025?” session at PCR London Valves conference. A Biomedical engineer, PhD and Xeltis Co-Founder, Martijn Cox will share his insights from Xeltis’ progressive developments and scientific knowledge.

“I’ve seen firsthand how much progress can be made in 10 years in medical technology; the healthcare landscape of 2025 may be exponentially more advanced,” he stated in anticipation of the discussion. “Medical innovation is changing healthcare treatment as we know it,” he added.

The interactive session, chaired by Prof Stephan Windecker, takes place on Sunday 24 September 4.40-5.30pm – Room 3 at ExCEl London.

PCR London Valves 2017 (24-26 September) focuses on transcatheter therapies for valvular heart disease. It is considered the world’s largest educational meeting focused on the care of patients with valvular heart disease, specifically addressing percutaneous valve interventions.

Learn more about Xeltis’ co-founder and PCR London Valves panelist Martijn Cox from this CTO profile.

Go back